TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3931536

Group type: EXPERIMENTAL
Intervention: Polydioxanone suture (PDS)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Polyamide (Nylon)
Number of subjects: 233
Study: 29703286

Group type: EXPERIMENTAL
Intervention: Riboflavin administration every 1 minute during UV-A exposure at 3mW/cm2
Number of subjects: 56

Group type: COMPARATOR
Intervention: Riboflavin administration every 2 minutes during UV-A exposure at 3mW/cm2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Transepithelial CXL
Number of subjects: 56
Study: 27157034

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) for emotional disorders
Number of subjects: 17
Study: 25899750

Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment (ON state)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ELEVATED plank condition
Number of subjects: 17

Group type: COMPARATOR
Intervention: GROUND plank condition
Number of subjects: 17
Study: 23765186

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 41
Study: 20495885

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Counseling (motivational interviewing)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755

Group type: COMPARATOR
Intervention: Counseling (health education)
Number of subjects: 755
Study: 18250350

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 1067
Study: 16700661

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 14580034

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections, dosage 10 to 50 U per site, total dose up to 200 U in the masticatory system, maximum 400 U if other sites included, injection frequency no more than once every 12 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections for chronic myofascial trigger points in painful muscles without observable involuntary movements.
Number of subjects: 0
Study: 10734752

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant or antiplatelet agents
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Previous thromboembolism
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Permanent atrial fibrillation
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Left atrium dilation
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients aged 80 years and over
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Non-permanent atrial fibrillation
Number of subjects: 302
Study: 9183756

Group type: EXPERIMENTAL
Intervention: 5-mm single ablation zone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6-mm single ablation zone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double ablation (multizone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 50
Study: 1534176

Group type: EXPERIMENTAL
Intervention: Ondansetron (12 mg orally over 24 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amphetamine (15 mg orally)
Number of subjects: 9
Study: 3519482

Group type: EXPERIMENTAL
Intervention: Ceftazidime 0.5 g every 8 hours for at least 5 days
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Ceftazidime 1.0 g every 8 hours for at least 5 days
Number of subjects: 197
Study: 29765876

Group type: EXPERIMENTAL
Intervention: Real rPMS treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rPMS treatment
Number of subjects: 26
Study: 26658133

Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24388868

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BUD/FM; Symbicort(®)) for maintenance and reliever therapy (SMART group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SM group, n=15)
Number of subjects: 30
Study: 22917936

Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (Ajust®)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Tension-free vaginal tape-obturator (TVT-O™)
Number of subjects: 137
Study: 20526776

Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 57
Study: 18403271

Group type: EXPERIMENTAL
Intervention: 10% mannitol iv in 1 L 0.9% NaCL for 4 hours for 5 consecutive days
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.9% NaCL (placebo)
Number of subjects: 41
Study: 16185958

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with porfimer sodium (PORPDT) plus omeprazole
Number of subjects: 208

Group type: COMPARATOR
Intervention: Omeprazole only (OM)
Number of subjects: 208
Study: 12947533

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing plus elastic compression (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unna boot (Group A)
Number of subjects: 60
Study: 10872850

Group type: EXPERIMENTAL
Intervention: Trillium Biopassive Surface (TBS) coated oxygenators
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional circuits
Number of subjects: 139
Study: 9182115

Group type: EXPERIMENTAL
Intervention: Netivudine 200 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netivudine (50 mg and 100 mg doses also tested)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netivudine (all doses)
Number of subjects: 0
Study: 1431261

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (AP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acellular diphtheria and tetanus toxoids pertussis vaccine (ADTP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Whole cell DTP
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ADTP
Number of subjects: 72

Group type: COMPARATOR
Intervention: DTP
Number of subjects: 72
Study: 6715565

Group type: EXPERIMENTAL
Intervention: Sulindac (150 and 200 mg, b.i.d.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Naproxen (250 and 375 mg, b.i.d.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin (650 and 975 mg, q.i.d.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29668399

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complementary and Alternative Medicine (CAM)
Number of subjects: 20
Study: 28418767

Group type: EXPERIMENTAL
Intervention: Survivorship care nurse counseling session coupled with individualized treatment summaries and survivorship care plans
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study: 25044819

Group type: EXPERIMENTAL
Intervention: One visit intervention (face-to-face home visit plus telephone calls)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Two visit intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 148
Study: 22979994

Group type: EXPERIMENTAL
Intervention: Pediatric BP-I disorder comorbid with ADHD
Number of subjects: 239

Group type: COMPARATOR
Intervention: Non-bipolar ADHD
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control children with neither ADHD nor BP-I disorder
Number of subjects: 239
Study: 21561956

Group type: EXPERIMENTAL
Intervention: 30 mg l-amphetamine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 18442722

Group type: EXPERIMENTAL
Intervention: RATG induction therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (conventional immunosuppression)
Number of subjects: 44
Study: 17181618

Group type: EXPERIMENTAL
Intervention: Millennium Custom Control Software (CCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 0
Study: 12889553

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 247
Study: 11126262

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 45
Study: 9015602

Group type: EXPERIMENTAL
Intervention: Randomised controlled studies
Number of subjects: 282
Study: 1317643

Group type: EXPERIMENTAL
Intervention: 3-mg PGE2 vaginal suppository
Number of subjects: 267

Group type: COMPARATOR
Intervention: 3-mg PGE2 vaginal tablet
Number of subjects: 267
Study: 6512894

Group type: EXPERIMENTAL
Intervention: Routine exploration for all injuries to the neck violating the platysma muscle (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Selective management based on clinical or radiographic evidence of major vascular, visceral, or airway injury (Group B)
Number of subjects: 160
Study: 30303628

Group type: EXPERIMENTAL
Intervention: Tylerdipine after a high-fat meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 14
Study: 29117072

Group type: EXPERIMENTAL
Intervention: Intermittent standing (4 h of sitting interrupted with four 10‐min bouts of standing)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intermittent desk pedaling (4 h of sitting interrupted with four 10‐min bouts of light-intensity desk pedaling)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uninterrupted sitting (4 h of uninterrupted sitting)
Number of subjects: 13
Study: 27260500

Group type: EXPERIMENTAL
Intervention: Early postnatal care three days after delivery provided in-person with a CHW using a simple checklist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care provided by phone with a CHW using the same checklist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 0
Study: 25056813

Group type: EXPERIMENTAL
Intervention: Peer support program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control care
Number of subjects: 0
Study: 22412170

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the unaffected hemisphere
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the affected hemisphere
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of rTMS and tDCS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (1 Hz rTMS only)
Number of subjects: 27
Study: 19254210

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day (n=17)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day (n=13)
Number of subjects: 30
Study: 17593772

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 36

Group type: COMPARATOR
Intervention: ID
Number of subjects: 36
Study: 15337403

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 882

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 882
Study: 11772251

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVIG infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamivudine and vidarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribavirin and IFN‐alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN‐alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulphamethoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide, colchicine, and dapsone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti‐lymphocytic monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow and stem cell transplantation
Number of subjects: 0
Study: 9647022

Group type: EXPERIMENTAL
Intervention: 2-day quadruple therapy (omeprazole 40 mg b.i.d., amoxicillin 2.5 g once daily, metronidazole 500 mg t.i.d., bismuth subcitrate 360 mg t.i.d. for 2 days, followed by omeprazole 20 mg once daily for 6 additional days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 14-day triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d., metronidazole 500 mg t.i.d.)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2-day quadruple therapy (per-protocol analysis)
Number of subjects: 81
Study: 9110943

Group type: EXPERIMENTAL
Intervention: Manual therapy in combination with other treatments
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 24
Study: 2038187

Group type: EXPERIMENTAL
Intervention: Complement fixation assay (CFA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Western blot (WB)
Number of subjects: 8
Study: 31036601

Group type: EXPERIMENTAL
Intervention: 35000HP
Number of subjects: 8

Group type: COMPARATOR
Intervention: FX548
Number of subjects: 8
Study: 29071915

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint application
Number of subjects: 62

Group type: COMPARATOR
Intervention: Medication (Budesonide Powder)
Number of subjects: 62
Study: 23410885

Group type: EXPERIMENTAL
Intervention: 20,000 IU/week oral vitamin D3 for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40,000 IU/week oral vitamin D3 for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 30
Study: 21330385

Group type: EXPERIMENTAL
Intervention: Total Face Mask (TFM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Oronasal Mask (ONM)
Number of subjects: 60
Study: 19167635

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valvotomy (PMV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Closed surgical commissurotomy (CSC)
Number of subjects: 40
Study: 16710109

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion SPECT with [(123)I]iodoamphetamine
Number of subjects: 20
Study: 14985215

Group type: EXPERIMENTAL
Intervention: 1 mg zeaxanthin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg zeaxanthin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg and 10 mg zeaxanthin
Number of subjects: 20
Study: 11449612

Group type: EXPERIMENTAL
Intervention: Flexible asthma control plan (ATACO)
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Conventional fixed-dose management (group B)
Number of subjects: 8000
Study: 9072854

Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurements (CCO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bolus thermodilution cardiac output determinations (BCO)
Number of subjects: 20
Study: 8448887

Group type: EXPERIMENTAL
Intervention: Budesonide pure powder (400 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2946609

Group type: EXPERIMENTAL
Intervention: Gaseous tubal insufflation
Number of subjects: 393

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 393

Group type: COMPARATOR
Intervention: Gaseous tubal insufflation vs HSG
Number of subjects: 393

Group type: COMPARATOR
Intervention: Gaseous tubal insufflation vs laparoscopy
Number of subjects: 393

Group type: COMPARATOR
Intervention: HSG and laparoscopy
Number of subjects: 393
Study: 29246678

Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self-Management Course (OPSMC)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: High-risk group (feedback of fracture risk)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Osteoporosis information leaflet (control)
Number of subjects: 470
Study: 27386010

Group type: EXPERIMENTAL
Intervention: LED activation of 35% hydrogen peroxide and 10% carbamide peroxide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser activation of 35% hydrogen peroxide and 10% carbamide peroxide
Number of subjects: 18
Study: 24772521

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg)
Number of subjects: 1758
Study: 22653382

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks (etanercept/etanercept group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly for 12 weeks (placebo/etanercept group)
Number of subjects: 77
Study: 20981351

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temocapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18028521

Group type: EXPERIMENTAL
Intervention: Narcotics Anonymous/Alcoholics Anonymous attendance
Number of subjects: 142
Study: 16103252

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing in the slow VT zone (101 to 148 bpm)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Monitoring group with no therapy in the slow VT zone
Number of subjects: 374
Study: 11815318

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) 400 microg daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5-Methyltetrahydrofolate (MTHF) 480 microg daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10078538

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (20, 40, and 80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral sildenafil (100, 150, and 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brachial artery infusion of sildenafil (up to 300 microg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (40 mg) in men with ischemic heart disease
Number of subjects: 0
Study: 7672465

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lorazepam (rectally administered)
Number of subjects: 102
Study: 1932612

Group type: EXPERIMENTAL
Intervention: 160 mg SR oxprenolol once every 24 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 mg RR oxprenolol once every 12 h
Number of subjects: 12
Study: 7073917

Group type: EXPERIMENTAL
Intervention: Phenoperidine analgesia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Extradural analgesia with 0.5% bupivacaine with adrenaline 1:200 000
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Postoperative blood loss
Number of subjects: 41
Study: 31611499

Group type: EXPERIMENTAL
Intervention: Nicardipine intraluminal administration in group A (no-touch SVG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nicardipine intraluminal administration in group B (conventional preparation)
Number of subjects: 59
Study: 31266825

Group type: EXPERIMENTAL
Intervention: Rescue group offered a blood test after 12 weeks of FIT nonparticipation
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Choice group given the option to choose a blood test instead of FIT at baseline
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rescue group
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Choice group
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: FIT test awareness
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Blood test awareness
Number of subjects: 1800
Study: 29294552

Group type: EXPERIMENTAL
Intervention: Electroencephalographic biofeedback therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Drugs to promote the metabolism of brain cells (Control)
Number of subjects: 52
Study: 25660759

Group type: EXPERIMENTAL
Intervention: Hypoxia (10% O2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham (21% O2)
Number of subjects: 22
Study: 24054383

Group type: EXPERIMENTAL
Intervention: Penile block
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 159

Group type: COMPARATOR
Intervention: Intravenous paracetamol
Number of subjects: 159
Study: 22051739

Group type: EXPERIMENTAL
Intervention: HPV screening
Number of subjects: 25061

Group type: COMPARATOR
Intervention: Cervical cytology
Number of subjects: 25061
Study: 19786134

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin chemoprophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BCG vaccination and rifampicin prophylaxis
Number of subjects: 0
Study: 18269772

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 15470624

Group type: EXPERIMENTAL
Intervention: Informed group (n=257)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Uninformed group (n=244)
Number of subjects: 501
Study: 11469941

Group type: EXPERIMENTAL
Intervention: Pre-packed chloroquine tablets
Number of subjects: 299

Group type: COMPARATOR
Intervention: Chloroquine syrup
Number of subjects: 299
Study: 10077773

Group type: EXPERIMENTAL
Intervention: SBT/ABPC 3 g i.v., b.i.d.
Number of subjects: 68

Group type: COMPARATOR
Intervention: CTM 1 g i.v., b.i.d.
Number of subjects: 68
Study: 8041543

Group type: EXPERIMENTAL
Intervention: Mental calculation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Noise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no stress)
Number of subjects: 22
Study: 3258429

Group type: EXPERIMENTAL
Intervention: High voltage electrical stimulation (daily from a commercial high voltage generator)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (electrodes applied daily but no stimulation)
Number of subjects: 16
Study: 31867616

Group type: EXPERIMENTAL
Intervention: Weekly oral cyclic antibiotic (WOCA) prophylaxis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 45
Study: 30849106

Group type: EXPERIMENTAL
Intervention: NMD-12 screening model
Number of subjects: 0
Study: 28481241

Group type: EXPERIMENTAL
Intervention: Galunisertib plus lomustine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Galunisertib
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Galunisertib monotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: T-regulatory cell compartment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo + lomustine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Lomustine monotherapy
Number of subjects: 158